Dr. John Cush RheumNow
2 months 4 weeks ago
FDA Targeting the Safety of Avacopan
The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market. https://t.co/4PyIoqwNIL
Dr. John Cush RheumNow
2 months 4 weeks ago
APR: Steroids
https://t.co/FxqGaijo6w https://t.co/OrybGNXsdf
Dr. John Cush RheumNow
2 months 4 weeks ago
EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Dr. John Cush RheumNow
2 months 4 weeks ago
Synovial tissue study from 244 #OA pts undergoing surgery, finds variable synovial pathotypes - High-grade synovitis in 64% (55% lympho-myeloid, 12% diffuse-myeloid, 33% pauci-immune). Lympho-myeloid had highest inflammation, incr by high BMI. https://t.co/cc0Z3KWtY0 https://t.co/zf7r23KGCy
Dr. John Cush RheumNow
2 months 4 weeks ago
RA is significantly associated with an increased risk of osteoporotic fractures (OPF) -RR 1.47 (1.32–1.64), for both female (1.39) & male(1.69) pts. Metanalysis of OPF in RA (7 cohort studies, 12,408pts). https://t.co/XP719A3ZM6 https://t.co/40phL7K9EB
Dr. John Cush RheumNow
3 months ago
Neoplasia and Autoimmune Disease
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune https://t.co/uIsVl1N1hH
Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Dr. John Cush RheumNow
3 months ago
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/mEaUcBD2ZK
Dr. John Cush RheumNow
3 months ago
Mexico study of SLE mortality in kids. Betw 2000-23, SLE accounted for 637/280,334 child deaths. Females (80%) had 4X higher deaths than males (ASMR 0.13 vs 0.03). No consistent trend in time for mortality. https://t.co/gkoXG90nLx https://t.co/BB0JhTHFKf
Suryansh Tiwari Suryanshti777
3 months ago
A man spends 50 years teaching at MIT.
He knows his time is running out.
So he records one last lecture — everything he knows, distilled into a single hour.
He died 5 months later.
This is that lecture.
The most important hour you'll watch this week. 👇
Bookmark it for later https://t.co/tRUH05ysSt
Dr. John Cush RheumNow
3 months ago
APR: Methotrexate
Companion slide deck for the Advanced Practice Rheum: Methotrexate video, featuring Dr. Jack Cush.
https://t.co/8422FKN4dq https://t.co/6gVS7dA8Gi
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.
